BACKGROUND: In the phase 3 RADIANT-4 trial, everolimus increased progression-free survival compared with placebo in patients with advanced, progressive, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (NETs). We now report the health-related quality of life (HRQOL) secondary endpoint. METHODS: RADIANT-4 is a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial done in 97 centres in 25 countries worldwide. Adults (aged ≥18 years) were eligible for the study if they had pathologically confirmed, advanced (unresectable or metastatic), non-functional, well-differentiated (grade 1 or 2) NETs of lung or gastrointestinal origin. Patients were randomly allocated (2:1) using block randomisation (block size of three) by an interactive voice response system to receive oral everolimus (10 mg per day) or placebo, both with best supportive care, with stratification by tumour origin, WHO performance status, and previous somatostatin analogue treatment. HRQOL was assessed with the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire at baseline (visit 2, day 1), every 8 weeks (± 1 week) during the study for the first 12 months after randomisation, and every 12 weeks thereafter until study drug discontinuation. The primary endpoint, reported previously, was progression-free survival assessed by central review; HRQOL was a prespecified secondary endpoint. The prespecified secondary outcome measure was time to definitive deterioration (≥7 points) in FACT-G total score. Analyses were done on the full analysis set, consisting of all randomised patients, by intention to treat. Only data obtained while receiving the randomly allocated treatment were included in this analysis. Enrolment for RADIANT-4 was completed on Aug 23, 2013, but the trial is ongoing pending final analysis of the key secondary endpoint of overall survival. This trial is registered with ClinicalTrials.gov, number NCT01524783. FINDINGS: Between April 3, 2012, and Aug 23, 2013, 302 patients were enrolled; 205 were randomly allocated everolimus and 97 were assigned placebo. At baseline, 193 (94%) of 205 patients assigned everolimus and 95 (98%) of 97 allocated placebo had completed either fully or partly the FACT-G questionnaire; at week 48, 70 (83%) of 84 patients assigned everolimus and 22 (85%) of 26 allocated placebo completed FACT-G. Median time to definitive deterioration in FACT-G total score was 11·27 months (95% CI 9·27-19·35) with everolimus and 9·23 months (5·52-not estimable) with placebo (adjusted hazard ratio 0·81, 95% CI 0·55-1·21; log-rank p=0·31). INTERPRETATION: HRQOL was maintained for patients with advanced, non-functional, gastrointestinal or lung NETs, with no relevant differences noted between the everolimus and placebo groups. In view of the previous RADIANT-4 findings of longer progression-free survival with everolimus, our findings suggest that everolimus delays disease progression while preserving overall HRQOL, even with the usual toxic effects related to active targeted drug treatment for cancer. FUNDING: Novartis Pharmaceuticals.

Clinic of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Faculty of Medicine Masaryk University Brno Czech Republic

Department of Gastrointestinal Medical Oncology Division of Cancer Medicine University of Texas MD Anderson Cancer Center Houston TX USA

Department of Gastrointestinal Oncology Moffitt Cancer Center Tampa FL USA

Department of Hepatology and Gastroenterology Charité Universitätsmedizin Berlin Campus Virchow Klinikum Berlin Germany; Department of Medicine 1 Division of Endocrinology Universitätsklinikum Erlangen Erlangen Germany

Department of Internal Medicine 1 Division of Oncology Klinik f Innere Medizin 1 AKH Vienna Austria

Department of Medical Oncology Antoni van Leeuwenhoek Amsterdam Netherlands

Department of Medical Oncology Montefiore Einstein Center for Cancer Care Bronx NY USA

Department of Medical Social Sciences Northwestern University Chicago IL USA

Division of Cancer Sciences Faculty of Biology Medicine and Health University of Manchester Manchester UK; Department of Medical Oncology The Christie NHS Foundation Trust Manchester UK

Division of Medical Oncology and Hematology Sunnybrook Health Sciences Centre Toronto ON Canada

Division of Surgical Oncology Oregon Health and Science University Portland OR USA

Klinik für Endokrinologie und Stoffwechselerkrankungen Universitaetsklinikum Essen Zentrum f Innere Medizin Essen Germany

Mapi Munich Germany

Mapi Stockholm Sweden

Medical Oncology and Solid Tumor Oncology Dana Farber Cancer Institute Boston MA USA

Medical Surgical Sciences and Translational Medicine Azienda Ospedaliera Sant'Andrea Università La Sapienza Rome Italy

Novartis Pharma AG Basel Switzerland

Novartis Pharmaceuticals Corporation East Hanover NJ USA

Oncology Unit Humanitas Clinical and Research Centre Rozzano Italy

S C Day Hospital e Terapia Ambulatoriale Oncologica Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Unit of Gastrointestinal Medical Oncology and Neuroendocrine Tumors European Institute of Oncology Milan Italy

University Hospitals Leuven and KU Leuven Digestive Oncology Leuven Belgium

Wellmera AG Basel Switzerland

Lancet Oncol. 2017 Oct;18(10):1299-1300. doi: 10.1016/S1470-2045(17)30618-6. PubMed

Citace poskytuje Crossref.org

Health-Related Quality of Life (HRQoL) Assessments in Research on Patients with Adult Rare Solid Cancers: A State-of-the-Art Review

Zobrazit více v PubMed

ClinicalTrials.gov
NCT01524783